N/A
Completed N=17,448
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
Source: ClinicalTrials.gov NCT01347060 ↗Enrolled (actual)
17,448
Serious AEs
—
Results posted
Jun 2011
Primary outcomePrimary: Mean Number of Post-index Asthma-related Events Measured Using Medical and Pharmacy Claims — 0.033; 0.046; 0.022; 0.027 Asthma-related events — p=0.0051
Summary
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a typical clinical practice using a retrospective observational cohort study design of large managed care database. Outcomes on interest include asthma related severe exacerbations defined as asthma related emergency department visits, hospitalizations or combined emergency department/hospitalization. Other outcomes of interest include use of albuterol, oral corticosteroids and overall asthma related costs. Outcomes of interest will be compared between the two treatment cohorts (fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids). Dichotomous outcomes (emergency visits, hospitalizations etc) will be compared using Cox regression hazards analysis assessing time to first event for each asthma related endpoint adjusting for differences in baseline demographics such as age, gender, previous asthma medication use, co morbidities, costs, and plan demographics. Total asthma related costs will also be compared using generalized linear models adjusting for baseline differences.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Number of Post-index Asthma-related Events Measured Using Medical and Pharmacy Claims |
0.033; 0.046; 0.022; 0.027; 0.05; 0.07 | 0.0051 sig |
| SECONDARY Mean Asthma-related Costs in the Post-index Period |
381; 462; 1128; 939; 1509; 1401 | 0.001 sig |
| SECONDARY Mean Number of Albuterol (Short-acting β-Agonists) Canisters Dispensed Per Pharmacy Claim Per Participant |
1.01; 1.5 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Subjects with asthma as determined by ICD-9 codes and asthma drug use
- at least 65 years of age
- prescription for an inhaled corticosteroid
Exclusion Criteria
- a diagnosis of chronic obstructive pulmonary disease or
- a prescription for a chronic obstructive pulmonary disease treatment
Data sourced from ClinicalTrials.gov (NCT01347060). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.